NEW YORK, May 6, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company's next generation, glycoengineered anti-CD20 monoclonal antibody and for TGR-1202, the Company's novel, once-daily PI3k delta inhibitor, at various upcoming conferences this summer.
Help employers find you! Check out all the jobs and post your resume.
